Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TESLAC is an oral small-molecule tablet approved by the FDA in 1970 as an NDA product developed by Bristol Myers Squibb. Specific mechanism of action and indication details are not available in current data, limiting characterization of its therapeutic use and patient population.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature asset with likely downsizing or transition planning underway within the commercial organization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job openings and LOE approaching, TESLAC represents a sunset career opportunity with minimal growth potential. Professionals on this asset should prioritize portfolio transitions to growth-stage products within Bristol Myers Squibb to advance career momentum.
Worked on TESLAC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.